|
|
||||||||
|
|
|||||||||
|
|
Neurosciences: NeurologyNeurology Posters |
1 Radiology; 2 Psychiatry, Johns Hopkins Medical Institutions, Baltimore, Maryland; 3 Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania
925
Objectives: Since the imaging of amyloid with [11C] PIB, a suitable radiotracer labeled with F-18 has been sought. Here we present the first human PET scans with [18F] AV-45.
Methods: Dynamic PET was using GE Advance included 6 Alzheimer AD), mean age 72.50 ± 11.4 (sd) and 6 healthy controls (HC) mean age 81 ± 7 yrs. Two HC were studied on PET/CT for radiation dosimetry. For AD mean MMSE was 18.17, logical memory 3.50, total ADS 23.50. Education was similar for both groups (12-20). All had co-registered SPGR MRIs. The mean specific activity for the AD and controls was 170 ± 75 and 210 ± 108 GBq/micromole, and the average IV injection of radioactivity was 9.3 ± 0.3 and 9.8 ± 0.7 mCi (344 and 362 MBq). A linear regression with spatial constraint for a simplified (DVR) image reference tissue method (Zhou et al, Neuroimage 2006) was used to generate the distribution volume ratio (DVR) maps.
Results: There were no adverse events with AV45. Radiation dosimetry was estimated at 0.02 mSv/MBq. Spatially normalized DVR images were generated from PET dynamic studies for the AD ranged from 1.34 to 1.42 in frontal, temporal, occipital, parietal cortex 1.6 (cingulate) and 1.5 (putamen). However for the HC the DVR were negligible (1.0 to 1.3) for the same regions. Multiple T tests showed significant increases in DVR for AD in all cortical and insular regions but not in subcortical, pons , white matter nor cerebellar regions.
Conclusions: 18F AV45 has a favorable toxicity/dosimetry profile and shows significant discrimination between AD and HC in cortex and cingulate with good characteristics for quantification.
Research Support: Avid Radiopharmaceuticals, Inc.
| ||||||||||||||||||||||||||||||||||||||